CoChat

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 17 of the 44 sources its claims cite were checked for support.

Abstract

Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris .

Overview

CoChat Summary

TL;DR

In a phase 2, open-label, single-arm trial, fosmanogepix was safe and efficacious in 9 ICU patients with candidemia caused by *Candida auris* in South Africa, with DRC-assessed treatment success at EOST and Day 30 survival both 89% (8/9). No treatment-related adverse events were reported, and manogepix showed low MICs against all baseline *C. auris* isolates.

Key findings

  • DRC-assessed treatment success at EOST was 89% (8/9; 95% CI 51.8–99.7), and Day 30 survival was 88.9% (8/9). The single EOST failure was a death on Day 11 considered unrelated to FMGX.
  • Mycological outcomes: 6/9 had eradication at EOST, 2 were indeterminate, and 1 had recurrence 2 days after stopping FMGX; sustained treatment success at 2 and 4 weeks after EOST was 66.7% (6/9).
  • Safety: all 9 participants had TEAEs (48 events), but 0 were study drug-related; 2 participants had 5 SAEs, all considered unrelated to treatment. Two deaths occurred, both assessed as unrelated to FMGX.
  • In vitro activity: manogepix MIC range was 0.008–0.015 μg/mL by CLSI and 0.004–0.03 μg/mL by EUCAST, with the lowest MICs among antifungals tested. Median total-drug plasma AUC was 93 mg·h/L, and median AUC:MIC ratio was 7147.

Methods

  • Multicenter, open-label, non-comparative, single-arm Phase 2 study (NCT04148287) planned at 4 South Africa sites and 1 Panama site; 9 adults with *C. auris* candidemia and limited treatment options were enrolled at 2 South Africa sites between 10 Dec 2019 and 23 Oct 2020.
  • Treatment: FMGX 1000 mg IV twice daily on Day 1, then 600 mg IV once daily; oral switch to 800 mg once daily was permitted from Day 4, up to 42 days. All participants received IV FMGX only.
  • Primary endpoint: DRC-assessed treatment success at EOST, defined as survival plus clearance of *C. auris* without additional antifungals. Secondary endpoints included Day 30 survival, time to first negative blood culture, mycological outcomes, safety, and in vitro susceptibility.

Limitations

  • The authors state the sample size was small because the study was terminated early due to the COVID-19 pandemic’s ICU burden; all active sites were in South Africa, isolates were likely Clade III, and results may not generalize to all clades.
  • The authors note participants had candidemia only, with no deep-seated *C. auris* infections, and PK sampling was sparse, precluding model-based compartmental analysis.
  • Evident from the text: the single-arm, open-label, non-comparative design with N=9 and wide confidence intervals limits causal inference; Table 5 also lists 1 TEAE leading to discontinuation of study drug, while the abstract/results state no study drug discontinuations were reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/aac.01419-22

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1 Study Design. For participants with invasive candidiasis, maintenance dosing was to continue until there was at least 1 negative tissue culture or aspirate/fluid. For participants with a deep-seated site of infection from which a tissue culture was not obtainable, maintenance dosing was to continue until after the resolution of the attributable clinical signs of infection recorded at baseline, and as applicable, radiological improvement associated with the site of infection. BID, twice daily; EOST, end of study treatment; FMGX, fosmanogepix; IV, intravenous; PO, orally; QD, once daily.
FIG 1 Study Design. For participants with invasive candidiasis, maintenance dosing was to continue until there was at least 1 negative tissue culture or aspirate/fluid. For participants with a deep-seated site of infection from which a tissue culture was not obtainable, maintenance dosing was to continue until after the resolution of the attributable clinical signs of infection recorded at baseline, and as applicable, radiological improvement associated with the site of infection. BID, twice daily; EOST, end of study treatment; FMGX, fosmanogepix; IV, intravenous; PO, orally; QD, once daily.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 3 Not valid · 17 Not checked · 54 Own results and interpretations

40 more claims · 1 with their cited sources checked

Create a free account to see all 84 claims and to verify the 27 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 10.1128/aac.01120-1 · doi:10.1128/aac.01120-1

Cited by

See all 92

Metadata

Authors
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R.
Affiliations
  • Medical College of Georgia, Augusta University, Augusta, Georgia, USA
  • University of Alabama at Birmingham (US)
  • University of the Witwatersrand (ZA)
  • Steve Biko Hospital (ZA)
  • Amplyx Pharmaceuticals (United States) (US)
  • Pfizer (United States) (US)
Corresponding author
Tawadrous, Margaret
Venue
Antimicrobial Agents and Chemotherapy
Published
2023-05-17
Volume
67
Issue
5
Pages
e0141922-e0141922
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W4362658239
Cited by
92
References
35
Citations by year
2026: 29 · 2025: 22 · 2024: 33 · 2023: 7
FWCI
18.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UpSpace Institutional Repository (University of Pretoria) (submittedVersion, cc-by)
Funders
Amplyx
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
fosmanogepix, Candida auris, candidemia, invasive candidiasis, antifungal agents, antifungal resistance, treatment efficacy, drug safety
MeSH terms
Candida auris, Antifungal Agents, Candidiasis, Female, Humans, Male, Microbial Sensitivity Tests, Treatment Outcome, Isocyanates, Candidiasis, Invasive, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.